Skip to main content
FDA fast-tracks Tonix's Alzheimer's disease drug
7/17/2018

Tonix Pharmaceuticals' TNX-102 SL was designated fast-track status by the FDA. The candidate is being developed as a treatment of agitation in patients with Alzheimer's disease.

Full Story: